JP2017519727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519727A5 JP2017519727A5 JP2016566962A JP2016566962A JP2017519727A5 JP 2017519727 A5 JP2017519727 A5 JP 2017519727A5 JP 2016566962 A JP2016566962 A JP 2016566962A JP 2016566962 A JP2016566962 A JP 2016566962A JP 2017519727 A5 JP2017519727 A5 JP 2017519727A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- thieno
- triazolo
- chlorophenyl
- hydroxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 16
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 9
- 239000007962 solid dispersion Substances 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- YBPAYPRLUDCSEY-UHFFFAOYSA-N 2-(4-hydroxyphenyl)acetamide Chemical compound NC(=O)CC1=CC=C(O)C=C1 YBPAYPRLUDCSEY-UHFFFAOYSA-N 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 230000009477 glass transition Effects 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461990457P | 2014-05-08 | 2014-05-08 | |
| US61/990,457 | 2014-05-08 | ||
| US201462012048P | 2014-06-13 | 2014-06-13 | |
| US62/012,048 | 2014-06-13 | ||
| US201462080751P | 2014-11-17 | 2014-11-17 | |
| US62/080,751 | 2014-11-17 | ||
| US201462086400P | 2014-12-02 | 2014-12-02 | |
| US62/086,400 | 2014-12-02 | ||
| US201562150044P | 2015-04-20 | 2015-04-20 | |
| US62/150,044 | 2015-04-20 | ||
| PCT/EP2015/060200 WO2015169951A1 (en) | 2014-05-08 | 2015-05-08 | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017519727A JP2017519727A (ja) | 2017-07-20 |
| JP2017519727A5 true JP2017519727A5 (enExample) | 2018-06-14 |
Family
ID=53191652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566962A Pending JP2017519727A (ja) | 2014-05-08 | 2015-05-08 | チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9968619B2 (enExample) |
| EP (1) | EP3139959A1 (enExample) |
| JP (1) | JP2017519727A (enExample) |
| KR (1) | KR20170002610A (enExample) |
| CN (1) | CN106852120A (enExample) |
| AU (1) | AU2015257658A1 (enExample) |
| BR (1) | BR112016026046A8 (enExample) |
| CA (1) | CA2947970A1 (enExample) |
| MX (1) | MX2016014574A (enExample) |
| RU (1) | RU2016147946A (enExample) |
| WO (1) | WO2015169951A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102216288B1 (ko) | 2013-03-15 | 2021-02-18 | 인사이트 홀딩스 코포레이션 | Bet 단백질 저해제로서의 삼환식 복소환 |
| ES2635560T3 (es) | 2013-07-08 | 2017-10-04 | Incyte Holdings Corporation | Heterociclos tricíclicos como inhibidores de la proteína NET |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| PT3134403T (pt) | 2014-04-23 | 2020-05-18 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas como inibidores das proteínas bet |
| WO2016044130A1 (en) | 2014-09-15 | 2016-03-24 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CN109715625B (zh) | 2016-06-20 | 2022-04-19 | 因赛特公司 | Bet抑制剂的结晶固体形式 |
| EP4118431A1 (de) * | 2020-03-12 | 2023-01-18 | Heinrich-Heine-Universität Düsseldorf | Inhibition von fkbp1a zur therapie des triple-negativen mammakarzinoms |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| BR112023025562A2 (pt) | 2021-06-08 | 2024-02-20 | Poseidon Innovation Llc | Compostos anticâncer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60039802D1 (de) * | 1999-02-10 | 2008-09-25 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung |
| CA2412776C (en) | 2000-06-16 | 2011-03-15 | Mitsubishi Pharma Corporation | Compositions controlling release ph range and/or speed |
| JP5478262B2 (ja) * | 2007-12-28 | 2014-04-23 | 田辺三菱製薬株式会社 | 抗癌剤 |
| CN104311562B (zh) | 2010-05-14 | 2017-07-04 | 达那-法伯癌症研究所 | 用于治疗瘤形成、炎性疾病和其他失调的组合物和方法 |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| US20130345145A1 (en) * | 2011-03-10 | 2013-12-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Atip3 and biologically active fragments thereof for use in the treatment of cancer |
| CA2877434A1 (en) | 2012-06-25 | 2014-01-03 | Oncoethix Sa | Method of treating lymphoma using thienotriazolodiazepine compounds |
| CA2876241A1 (en) * | 2012-06-27 | 2014-01-03 | The Curators Of The University Of Missouri | Induction of estrogen receptor beta by cholesterol biosynthesis inhibitors and methods of treatment of cancer |
| BR112015006537A2 (pt) | 2012-09-28 | 2017-07-04 | Oncoethix Sa | dispersão sólida, formulação farmacêutica, cápsula farmacêutica, e, tablete farmacêutico |
| ES2656640T3 (es) * | 2012-10-04 | 2018-02-27 | Ab Science | Uso de masitinib en combinación con gemcitabina para tratamiento de un subgrupo de pacientes que sufren de cáncer pancreático |
| US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| WO2015018523A1 (en) | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A novel bet-brd inhibitor for treatment of solid tumors |
-
2015
- 2015-05-08 MX MX2016014574A patent/MX2016014574A/es unknown
- 2015-05-08 JP JP2016566962A patent/JP2017519727A/ja active Pending
- 2015-05-08 WO PCT/EP2015/060200 patent/WO2015169951A1/en not_active Ceased
- 2015-05-08 CN CN201580037334.9A patent/CN106852120A/zh active Pending
- 2015-05-08 EP EP15723671.2A patent/EP3139959A1/en not_active Withdrawn
- 2015-05-08 BR BR112016026046A patent/BR112016026046A8/pt not_active IP Right Cessation
- 2015-05-08 CA CA2947970A patent/CA2947970A1/en not_active Abandoned
- 2015-05-08 US US15/308,525 patent/US9968619B2/en not_active Expired - Fee Related
- 2015-05-08 RU RU2016147946A patent/RU2016147946A/ru not_active Application Discontinuation
- 2015-05-08 KR KR1020167034522A patent/KR20170002610A/ko not_active Withdrawn
- 2015-05-08 AU AU2015257658A patent/AU2015257658A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519727A5 (enExample) | ||
| RU2016147946A (ru) | Способ лечения трижды негативного рака молочной железы с использованием тиенотриазолодиазепиновых соединений | |
| JP2017529332A5 (enExample) | ||
| RU2017100921A (ru) | Способ лечения немелкоклеточного рака легких и/или мелкоклеточного рака легких с применением соединений тиенотриазолодиазепина | |
| CY1125110T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| JP2013510123A5 (enExample) | ||
| JP2012136540A5 (enExample) | ||
| RU2014124184A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5 | |
| JP2013510124A5 (enExample) | ||
| JP2016530283A5 (enExample) | ||
| JP2016529246A5 (enExample) | ||
| JP2013529611A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JP2018501315A5 (enExample) | ||
| RU2014105577A (ru) | Капсулированная лекарственная форма, содержащая монтелукаст и левоцетиризин | |
| JP2016516067A5 (enExample) | ||
| PH12020500327A1 (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| JP2017517579A5 (enExample) | ||
| JP2019512535A5 (enExample) | ||
| JP2015504091A5 (enExample) | ||
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| EA201791289A1 (ru) | Ингибиторы клеточного некроза и связанные с ними способы | |
| CY1123346T1 (el) | Παραγωγα 5-[2-(πυριδιν-2-υλαμινο)-1,3-θειαζολ-5-υλ]-2,3-διυδρο-1η-ισοϊνδολ-1-ονης και χρηση τους ως διπλοι αναστολεις της 3-κινασης φωσφατιδυλοϊνοσιτολης δελτα & γαμμα | |
| CO6612185A2 (es) | Composiciones famacéuticas para el tratamiento del cáncer y otras enfermedades o transtornos | |
| CN110267954A (zh) | 苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 |